JP2020530440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530440A5 JP2020530440A5 JP2020500113A JP2020500113A JP2020530440A5 JP 2020530440 A5 JP2020530440 A5 JP 2020530440A5 JP 2020500113 A JP2020500113 A JP 2020500113A JP 2020500113 A JP2020500113 A JP 2020500113A JP 2020530440 A5 JP2020530440 A5 JP 2020530440A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- immune cell
- immune
- cell
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002865 immune cell Anatomy 0.000 claims description 98
- 239000000203 mixture Substances 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 40
- 102000004127 Cytokines Human genes 0.000 claims description 35
- 108090000695 Cytokines Proteins 0.000 claims description 35
- 108091033319 polynucleotide Proteins 0.000 claims description 31
- 239000002157 polynucleotide Substances 0.000 claims description 31
- 102000040430 polynucleotide Human genes 0.000 claims description 31
- 239000003102 growth factor Substances 0.000 claims description 29
- 108020004999 messenger RNA Proteins 0.000 claims description 21
- -1 method Substances 0.000 claims description 20
- 230000008685 targeting Effects 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 230000004927 fusion Effects 0.000 claims description 16
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 claims description 4
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 3
- 238000002659 cell therapy Methods 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 claims description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 2
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims description 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims description 2
- 101001018021 Homo sapiens T-lymphocyte surface antigen Ly-9 Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 102100029216 SLAM family member 5 Human genes 0.000 claims description 2
- 102100033447 T-lymphocyte surface antigen Ly-9 Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000001638 lipofection Methods 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762528411P | 2017-07-03 | 2017-07-03 | |
| US62/528,411 | 2017-07-03 | ||
| US201762598433P | 2017-12-13 | 2017-12-13 | |
| US62/598,433 | 2017-12-13 | ||
| US201862620107P | 2018-01-22 | 2018-01-22 | |
| US201862620418P | 2018-01-22 | 2018-01-22 | |
| US62/620,418 | 2018-01-22 | ||
| US62/620,107 | 2018-01-22 | ||
| US201862657455P | 2018-04-13 | 2018-04-13 | |
| US62/657,455 | 2018-04-13 | ||
| PCT/US2018/040783 WO2019010222A2 (en) | 2017-07-03 | 2018-07-03 | POLYNUCLEOTIDES ENCODING IMMUNOSTIMULATING FUSION MOLECULES AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530440A JP2020530440A (ja) | 2020-10-22 |
| JP2020530440A5 true JP2020530440A5 (enExample) | 2021-08-12 |
Family
ID=64950351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500113A Pending JP2020530440A (ja) | 2017-07-03 | 2018-07-03 | 免疫刺激性融合分子をコードするポリヌクレオチドおよびその使用 |
| JP2020500048A Pending JP2020530280A (ja) | 2017-07-03 | 2018-07-03 | 免疫刺激性融合分子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500048A Pending JP2020530280A (ja) | 2017-07-03 | 2018-07-03 | 免疫刺激性融合分子およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200306301A1 (enExample) |
| EP (3) | EP3675892A4 (enExample) |
| JP (2) | JP2020530440A (enExample) |
| KR (1) | KR20200037781A (enExample) |
| CN (2) | CN111094330A (enExample) |
| AU (4) | AU2018297248A1 (enExample) |
| CA (3) | CA3069105A1 (enExample) |
| GB (1) | GB2580228B (enExample) |
| WO (3) | WO2019010224A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202235438A (zh) | 2016-11-28 | 2022-09-16 | 日商中外製藥股份有限公司 | 能夠調節配體結合活性的配體結合分子 |
| MX2019005756A (es) | 2016-11-28 | 2019-08-14 | Chugai Pharmaceutical Co Ltd | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| CN111094330A (zh) | 2017-07-03 | 2020-05-01 | 转矩医疗股份有限公司 | 编码免疫刺激融合分子的多核苷酸及其用途 |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| TWI901940B (zh) | 2017-08-03 | 2025-10-21 | 美商安進公司 | 介白素-21突變蛋白及治療方法 |
| US20190070262A1 (en) | 2017-09-06 | 2019-03-07 | Yale University | Interleukin-18 variants and methods of use |
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| EP3719035A4 (en) | 2017-11-28 | 2021-09-01 | Chugai Seiyaku Kabushiki Kaisha | POLYPEPTIDE WITH ANTIGEN-BINDING AREA AND CARRYING SECTION |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| JP2019122373A (ja) | 2018-01-12 | 2019-07-25 | アムジエン・インコーポレーテツド | 抗ｐｄ−１抗体及び治療方法 |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US11904081B2 (en) | 2018-05-11 | 2024-02-20 | Lupagen, Inc. | Systems and methods for closed loop, real-time modifications of patient cells |
| EP3796977A4 (en) * | 2018-05-17 | 2022-03-02 | The Board of Trustees of the Leland Stanford Junior University | RECEPTOR INHIBITION BY PHOSPHATASE RECRUITMENT |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2020141974A1 (en) * | 2018-12-31 | 2020-07-09 | Merus N.V. | Truncated multivalent multimers |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CA3128518A1 (en) * | 2019-02-01 | 2020-08-06 | Actinium Pharmaceuticals, Inc. | Molecules and their derivatives directed against cd45 |
| KR20210124236A (ko) * | 2019-02-08 | 2021-10-14 | 비온테크 쎌 & 제네 테라피스 게엠베하 | Car-조작된 t 세포 및 사이토카인을 수반한 치료 |
| WO2020165374A1 (en) * | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| WO2020172631A2 (en) | 2019-02-21 | 2020-08-27 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN121971599A (zh) | 2019-02-25 | 2026-05-05 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| BR112021019471A2 (pt) * | 2019-03-29 | 2022-04-26 | Torque Therapeutics Inc | Composições imunoterapêuticas e uso das mesmas |
| AU2020279112A1 (en) | 2019-05-17 | 2021-12-02 | Xencor, Inc. | IL-7-Fc-fusion proteins |
| CA3141327A1 (en) * | 2019-05-20 | 2020-11-26 | Pandion Operations, Inc. | Madcam targeted immunotolerance |
| CN114008082A (zh) * | 2019-06-24 | 2022-02-01 | 南京金斯瑞生物科技有限公司 | 单克隆抗体-细胞因子融合蛋白二聚体及其应用 |
| TW202115115A (zh) * | 2019-07-02 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | 免疫結合物 |
| AU2020315213A1 (en) * | 2019-07-17 | 2022-02-03 | National University Of Singapore | Functional binders synthesized and secreted by immune cells |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| EP4019536A4 (en) * | 2019-08-19 | 2023-09-06 | Nantong Yichen Biopharma. Co. Ltd. | Immunocytokine, preparation for same, and uses thereof |
| CN110731968A (zh) * | 2019-09-10 | 2020-01-31 | 南京鼓楼医院 | Icos+cxcr3+调节性t细胞在制备预防重症肺炎药物中的应用 |
| RU2753282C2 (ru) * | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
| EP3795583A1 (en) * | 2019-09-19 | 2021-03-24 | Ecole Polytechnique Federale de Lausanne (EPFL) | Il10/fc fusion proteins useful as enhancers of immunotherapies |
| JP7716399B2 (ja) * | 2019-11-01 | 2025-07-31 | ブイオーアール バイオファーマ インコーポレーテッド | 抗－ｃｄ４５抗体及びそのコンジュゲート |
| US10792360B1 (en) * | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| EP4069291A1 (en) | 2019-12-03 | 2022-10-12 | Evotec International GmbH | Interferon-associated antigen binding proteins and uses thereof |
| CN115551887A (zh) * | 2019-12-05 | 2022-12-30 | 维萨列克斯股份有限公司 | 通用细胞疗法的免疫逃逸机制的调节剂 |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| US20230141575A1 (en) * | 2020-03-18 | 2023-05-11 | City Of Hope | Multivalent chemokine receptor binding complexes |
| JP2023526282A (ja) | 2020-05-13 | 2023-06-21 | ボナム セラピューティクス，インク． | タンパク質複合体の組成物及びその使用方法 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| WO2021242989A1 (en) * | 2020-05-29 | 2021-12-02 | Health Research, Inc. | Compositions and methods for inducing cas9 protein expression by use of autonomous pd-1 promoter activity |
| CN116322740A (zh) * | 2020-07-13 | 2023-06-23 | 特兰斯吉恩股份有限公司 | 免疫抑制的治疗 |
| US20230338531A1 (en) * | 2020-08-20 | 2023-10-26 | City Of Hope | Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells |
| EP4228610A1 (en) | 2020-10-13 | 2023-08-23 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
| US12024559B2 (en) | 2020-10-23 | 2024-07-02 | Asher Biotherapeutics, Inc. | Fusions with CD8 antigen binding molecules for modulating immune cell function |
| AU2021389989A1 (en) * | 2020-11-27 | 2023-06-08 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfβeta |
| AU2021391924A1 (en) | 2020-12-04 | 2023-06-22 | The General Hospital Corporation | Methods of using interleukin-2 agents |
| AU2021397271A1 (en) * | 2020-12-09 | 2023-07-06 | Asher Biotherapeutics, Inc. | Targeted cytokine construct for engineered cell therapy |
| WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| JP2024506292A (ja) * | 2021-02-05 | 2024-02-13 | サルブリス バイオセラピューティクス，インコーポレイティド | Ｉｌ－１５融合タンパク質と、その製造法ならびに利用法 |
| UY39638A (es) * | 2021-02-19 | 2022-08-31 | Janssen Biotech Inc | Materiales y métodos para dirigirse a las células t reguladoras para potenciar la vigilancia inmunitaria |
| KR20230147619A (ko) * | 2021-02-26 | 2023-10-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 외인적으로 도입된 사이토카인을 발현하는 조작된 면역이펙터 세포 |
| EP4314073A4 (en) * | 2021-03-24 | 2025-02-19 | Alkermes, Inc. | Upar antibodies and fusion proteins with the same |
| WO2022212593A1 (en) * | 2021-03-31 | 2022-10-06 | The Regents Of The University Of California | Bispecific binding agent-ligand fusions for the degradation of target proteins |
| KR102604849B1 (ko) * | 2021-05-11 | 2023-11-22 | 가톨릭대학교 산학협력단 | 항-cd25 항체, il-10 및 cxcr3를 발현하는 미니서클 벡터 |
| GB2638094B (en) | 2021-05-19 | 2026-03-04 | Asher Biotherapeutics Inc | IL-21 Polypeptides And Targeted Constructs |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| CN113444744A (zh) * | 2021-06-28 | 2021-09-28 | 北京鼎成肽源生物技术有限公司 | 一种用于基因编辑NK细胞的mRNA模板及构建方法、mRNA的体外转录方法和应用 |
| KR20240035556A (ko) | 2021-07-19 | 2024-03-15 | 추가이 세이야쿠 가부시키가이샤 | 융합 폴리펩타이드를 이용하는 프로테아제 매개성의 표적 특이적 사이토카인 송달 |
| JP2024538749A (ja) * | 2021-10-10 | 2024-10-23 | エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド | 抗ｐｄ－ｌ１／ｉｌ－１０融合タンパク質を用いて疾患を処置する方法 |
| EP4433512A4 (en) * | 2021-11-19 | 2025-12-31 | Univ Pennsylvania | Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy |
| CN120131911A (zh) * | 2021-12-01 | 2025-06-13 | 威特拉公司 | 使用白细胞介素-2药剂的方法 |
| CN116376942A (zh) * | 2021-12-31 | 2023-07-04 | 广州国家实验室 | mRNA疫苗 |
| US20230279130A1 (en) * | 2022-01-14 | 2023-09-07 | Qilu Puget Sound Biotherapeutics Corporation | Anti-ccr8 antibodies |
| US20250101107A1 (en) * | 2022-01-20 | 2025-03-27 | Repertoire Immune Medicines, Inc. | Cd8-targeted il-12 fusion proteins |
| WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| JP2025510189A (ja) * | 2022-03-24 | 2025-04-14 | アクティニウム ファーマシューティカルズ インコーポレイテッド | ヒト化抗ｃｄ４５抗体 |
| EP4507705A1 (en) * | 2022-04-13 | 2025-02-19 | President and Fellows of Harvard College | Compositions and methods for localized delivery of cytokines for adoptive cell therapy |
| AU2023259161A1 (en) * | 2022-04-27 | 2024-11-28 | Asher Biotherapeutics, Inc. | Combination of cytokine fusion proteins with cd8 antigen binding molecules |
| CN116854821A (zh) * | 2022-08-15 | 2023-10-10 | 海徕科(北京)生物技术有限公司 | IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途 |
| WO2024055040A2 (en) * | 2022-09-09 | 2024-03-14 | Actinium Pharmaceuticals, Inc. | Humanized anti-cd45 antibodies |
| TW202417511A (zh) * | 2022-10-12 | 2024-05-01 | 大陸商蘇州創勝醫藥集團有限公司 | 包含抗ｖｅｇｆｒ２抗體的製劑 |
| EP4611838A1 (en) * | 2022-11-01 | 2025-09-10 | Lupagen, Inc. | Devices and methods for extracorporeal cell treatment |
| EP4634216A1 (en) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| WO2024178305A1 (en) * | 2023-02-24 | 2024-08-29 | Modernatx, Inc. | Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer |
| WO2024178414A2 (en) * | 2023-02-24 | 2024-08-29 | The Wistar Institute Of Anatomy And Biology | Epitope editing and multi-specific immunce-cell engager therapy and methods of use |
| CN121793982A (zh) * | 2023-04-17 | 2026-04-03 | 扎格生物公司 | 组织定向抗体以及其使用方法 |
| WO2024254514A1 (en) * | 2023-06-08 | 2024-12-12 | The University Of North Carolina At Chapel Hill | Engineered antibody fusion proteins with modulable binding constants and their applications |
| WO2025072623A1 (en) * | 2023-09-28 | 2025-04-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting immune cells |
| WO2025080338A1 (en) * | 2023-10-11 | 2025-04-17 | Massachusetts Institute Of Technology | Cell-surface anchored cytokine therapy |
| WO2026015637A1 (en) * | 2024-07-10 | 2026-01-15 | The Trustees Of Dartmouth College | Treg targeted il-2 fusion proteins and therapeutic use thereof |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US5405940A (en) | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
| PT1037927E (pt) | 1997-12-08 | 2004-10-29 | Emd Lexigen Res Ct Corp | Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral |
| ATE329622T1 (de) | 1998-04-15 | 2006-07-15 | Lexigen Pharm Corp | Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor |
| US8119101B2 (en) | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
| US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| BR0013231A (pt) | 1999-08-09 | 2002-07-23 | Lexigen Pharm Corp | Complexos citocina-anticorpo múltiplos |
| JP5390055B2 (ja) * | 2000-06-29 | 2014-01-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強 |
| CA2445746C (en) * | 2001-04-30 | 2012-09-18 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| ATE542137T1 (de) | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | Immunocytokine mit modulierter selektivität |
| US20030175270A1 (en) * | 2002-01-17 | 2003-09-18 | Josef Penninger | Methods of regulating cytokine receptor signaling |
| US8287864B2 (en) | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| US20070003514A1 (en) | 2002-04-05 | 2007-01-04 | The Regents Of The University Of California | Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination |
| US7906118B2 (en) | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| US7615223B2 (en) | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
| EP1418184A1 (en) | 2002-11-08 | 2004-05-12 | Cell Center Cologne GmbH | Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof |
| EP1638510B1 (en) | 2003-07-01 | 2015-09-02 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| ES2399050T3 (es) | 2003-12-10 | 2013-03-25 | Medarex, Inc. | Anticuerpos contra interferón alfa y sus usos |
| US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| US8034352B2 (en) | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US9931413B2 (en) | 2005-04-06 | 2018-04-03 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US20120237442A1 (en) | 2005-04-06 | 2012-09-20 | Ibc Pharmaceuticals, Inc. | Design and Construction of Novel Multivalent Antibodies |
| US9623115B2 (en) | 2005-04-06 | 2017-04-18 | Ibc Pharmaceuticals, Inc. | Dock-and-Lock (DNL) Complexes for Disease Therapy |
| AU2006232310B9 (en) | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| US8067006B2 (en) | 2005-04-06 | 2011-11-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
| KR101281208B1 (ko) | 2005-05-11 | 2013-07-26 | 필로겐 에스.피.에이. | 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| CN105709237A (zh) | 2005-12-16 | 2016-06-29 | Ibc 医药公司 | 基于免疫球蛋白的多价生物活性装配体 |
| EP1966238B1 (en) | 2005-12-30 | 2012-04-25 | Merck Patent GmbH | Interleukin-12p40 variants with improved stability |
| JP5779090B2 (ja) * | 2008-04-09 | 2015-09-16 | マックスサイト インコーポレーティッド | 新規に単離された細胞の治療組成物の操作および送達 |
| EP3936122A1 (en) | 2008-11-24 | 2022-01-12 | Massachusetts Institute Of Technology | Methods and compositions for localized agent delivery |
| EP3243527B1 (en) | 2009-02-13 | 2019-06-05 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| US20110165122A1 (en) * | 2009-11-10 | 2011-07-07 | The Regents Of The University Of California | Method for targeted and sustained antiviral therapy |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011090492A1 (en) | 2010-01-19 | 2011-07-28 | Immunomedics, Inc. | Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
| CN101829322A (zh) * | 2010-03-05 | 2010-09-15 | 孙嘉琳 | 细胞因子-超抗原融合蛋白在制备抗实体瘤药物的应用 |
| WO2011112935A2 (en) | 2010-03-12 | 2011-09-15 | The Regents Of The University Of California | Antibody fusion proteins with disrupted heparin-binding activity |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| ES2674567T3 (es) * | 2010-05-21 | 2018-07-02 | Merrimack Pharmaceuticals, Inc. | Proteínas de fusión biespecíficas |
| WO2012019157A2 (en) * | 2010-08-06 | 2012-02-09 | The Regents Of The University Of California | Expression and purification of fusion protein with multiple mbp tags |
| EP2619229B1 (en) * | 2010-09-21 | 2016-04-06 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| ES3005233T3 (en) * | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| CA2819074C (en) * | 2010-12-06 | 2020-04-14 | Shell Internationale Research Maatschappij B.V. | Process for removing mercaptans from a gas stream |
| EP3626739A1 (en) * | 2011-06-24 | 2020-03-25 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| WO2013014149A1 (en) | 2011-07-27 | 2013-01-31 | Philogen S.P.A. | Il-12 immunoconjugate |
| WO2013052484A1 (en) | 2011-10-03 | 2013-04-11 | Immunomedics, Inc. | Dye conjugated peptides for fluorescent imaging |
| WO2013059885A2 (en) * | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| WO2013082254A1 (en) | 2011-12-02 | 2013-06-06 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors |
| CA2866126A1 (en) | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| EP3878964A1 (en) | 2012-11-27 | 2021-09-15 | Ajou University Industry-Academic Cooperation Foundation | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| WO2014174105A1 (en) | 2013-04-25 | 2014-10-30 | Philochem Ag | Antibody-drug conjugates |
| RU2655439C2 (ru) | 2013-05-31 | 2018-05-28 | Займворкс Инк. | Гетеромультимеры с уменьшенной или подавленной эффекторной функцией |
| CA2953287A1 (en) | 2013-06-19 | 2014-12-24 | Massachusetts Institute Of Technology | In vivo targeting of cells with ligand-conjugated particles |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| CA2925304C (en) | 2013-09-27 | 2023-04-18 | Massachusetts Institute Of Technology | Carrier-free biologically-active protein nanostructures |
| CA2951604A1 (en) | 2014-08-29 | 2016-03-03 | Pablo Umana | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
| WO2016048903A1 (en) | 2014-09-22 | 2016-03-31 | Intrexon Corporation | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| WO2016086186A2 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| WO2016112983A1 (en) * | 2015-01-15 | 2016-07-21 | Biontech Ag | Cytokine fusion proteins |
| US10227411B2 (en) * | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| US11022615B2 (en) * | 2015-05-04 | 2021-06-01 | University Of Florida Research Foundation, Inc. | Regulatory T-cells, method for their isolation and uses |
| WO2016187514A1 (en) * | 2015-05-21 | 2016-11-24 | Actinium Pharmaceueuticals, Inc. | Infusion administration of conjugated monoclonal antibodies |
| TW202444897A (zh) * | 2015-06-25 | 2024-11-16 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| AU2016305087B2 (en) | 2015-08-12 | 2022-01-20 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
| AU2016334401A1 (en) | 2015-10-10 | 2018-04-26 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| US20190000989A1 (en) | 2016-01-11 | 2019-01-03 | STC Biologics Inc. | Bispecific targeting agents and methods for their preparation |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| CA3031955A1 (en) | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| KR102050463B1 (ko) | 2016-08-10 | 2019-11-29 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 |
| WO2018030806A1 (ko) | 2016-08-10 | 2018-02-15 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
| CN110267978A (zh) | 2016-10-07 | 2019-09-20 | 得克萨斯大学体系董事会 | 用于治疗癌症的表达膜锚定的il-12的t细胞 |
| KR20180071193A (ko) | 2016-12-19 | 2018-06-27 | 한미약품 주식회사 | 뇌 표적 지속성 단백질 결합체 |
| AU2018215840A1 (en) | 2017-02-03 | 2019-08-01 | Hanmi Pharm. Co., Ltd. | Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof |
| KR20190126182A (ko) | 2017-03-27 | 2019-11-08 | 난트셀, 인크. | aNK 및 IL-12 조성물 및 방법 (ANK AND IL-12 COMPOSITIONS AND METHODS) |
| US11421011B2 (en) | 2017-05-18 | 2022-08-23 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| JP2020524512A (ja) | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法 |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| CN111094330A (zh) | 2017-07-03 | 2020-05-01 | 转矩医疗股份有限公司 | 编码免疫刺激融合分子的多核苷酸及其用途 |
| WO2019129053A1 (zh) | 2017-12-26 | 2019-07-04 | 南京金斯瑞生物科技有限公司 | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 |
| WO2019166946A1 (en) | 2018-02-28 | 2019-09-06 | Pfizer Inc. | Il-15 variants and uses thereof |
| CN110396133B (zh) | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| WO2019222294A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| EP3831945A4 (en) | 2018-07-30 | 2022-05-04 | Jinyu Zhang | PROTEIN HETERODIMER AND ITS USE |
| AU2019328575B2 (en) | 2018-08-30 | 2024-07-11 | Immunitybio, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| EP3856229A1 (en) | 2018-09-28 | 2021-08-04 | Pierre Fabre Medicament | New immunocytokines for the treatment of cancer |
| WO2020088631A1 (en) | 2018-11-01 | 2020-05-07 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| JP2022513600A (ja) | 2018-11-15 | 2022-02-09 | トルク セラピューティクス， インコーポレイテッド | がん免疫療法のための方法および組成物 |
| MX2021006922A (es) | 2018-12-11 | 2021-09-30 | Oncosec Medical Inc | Constructo multigenico para la expresión de proteínas inmunoduladoras y métodos de uso. |
| EP3897851A2 (en) | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
| BR112021019471A2 (pt) | 2019-03-29 | 2022-04-26 | Torque Therapeutics Inc | Composições imunoterapêuticas e uso das mesmas |
| CN111848810B (zh) | 2019-04-28 | 2024-08-23 | 张晋宇 | 一种蛋白质分子及其用途 |
| CA3142738A1 (en) | 2019-06-05 | 2020-12-10 | Asher Biotherapeutics, Inc. | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function |
| MA56520A (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Construction de l'interleukine 12 recombinante et ses utilisations |
| CN114008082A (zh) | 2019-06-24 | 2022-02-01 | 南京金斯瑞生物科技有限公司 | 单克隆抗体-细胞因子融合蛋白二聚体及其应用 |
| TW202115115A (zh) | 2019-07-02 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | 免疫結合物 |
| WO2021041715A2 (en) | 2019-08-30 | 2021-03-04 | University Of Kansas | Compositions including igg fc mutations and uses thereof |
| JP7483896B2 (ja) | 2020-01-17 | 2024-05-15 | エショー バイオセラピー， インク． | オフターゲット毒性を低下させるプロ抗体 |
| EP3889183A1 (en) | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
-
2018
- 2018-07-03 CN CN201880056938.1A patent/CN111094330A/zh active Pending
- 2018-07-03 WO PCT/US2018/040786 patent/WO2019010224A1/en not_active Ceased
- 2018-07-03 JP JP2020500113A patent/JP2020530440A/ja active Pending
- 2018-07-03 CA CA3069105A patent/CA3069105A1/en active Pending
- 2018-07-03 EP EP18828706.4A patent/EP3675892A4/en not_active Withdrawn
- 2018-07-03 CN CN201880056956.XA patent/CN111093689A/zh active Pending
- 2018-07-03 AU AU2018297248A patent/AU2018297248A1/en not_active Abandoned
- 2018-07-03 EP EP18827456.7A patent/EP3648786A4/en not_active Withdrawn
- 2018-07-03 KR KR1020207003059A patent/KR20200037781A/ko not_active Abandoned
- 2018-07-03 GB GB2001438.7A patent/GB2580228B/en not_active Expired - Fee Related
- 2018-07-03 JP JP2020500048A patent/JP2020530280A/ja active Pending
- 2018-07-03 AU AU2018298060A patent/AU2018298060B2/en not_active Ceased
- 2018-07-03 CA CA3069017A patent/CA3069017A1/en active Pending
- 2018-07-03 WO PCT/US2018/040783 patent/WO2019010222A2/en not_active Ceased
- 2018-07-03 WO PCT/US2018/040777 patent/WO2019010219A1/en not_active Ceased
- 2018-07-03 US US16/628,363 patent/US20200306301A1/en not_active Abandoned
- 2018-07-03 AU AU2018298063A patent/AU2018298063A1/en not_active Abandoned
- 2018-07-03 US US16/628,374 patent/US20210017247A1/en not_active Abandoned
- 2018-07-03 CA CA3068841A patent/CA3068841A1/en active Pending
- 2018-07-03 EP EP18827557.2A patent/EP3649147A4/en not_active Withdrawn
- 2018-07-03 US US16/628,342 patent/US11471490B2/en active Active
-
2021
- 2021-05-17 AU AU2021203162A patent/AU2021203162A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zheng et al. | The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy | |
| Overwijk et al. | Engineering IL-2 to give new life to T cell immunotherapy | |
| JP7207786B2 (ja) | インターロイキン２１タンパク質（ｉｌ２１）変異体およびその適用 | |
| Rohaan et al. | Adoptive cellular therapies: the current landscape | |
| Wu et al. | Chimeric antigen receptor therapy meets mRNA technology | |
| Khan et al. | Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors | |
| CN109952309B (zh) | 用于细胞治疗的组成型活性细胞因子受体 | |
| Redeker et al. | Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination | |
| Tzeng et al. | In situ genetic engineering of tumors for long-lasting and systemic immunotherapy | |
| Kim et al. | Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7 | |
| JP2020530280A5 (enExample) | ||
| Uricoli et al. | Engineered cytokines for cancer and autoimmune disease immunotherapy | |
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| GB2580228A (en) | Immunostimulatory fusion molecules and uses thereof | |
| TW201734205A (zh) | 表現免疫機能控制因子之免疫活性細胞及表現載體 | |
| WO1996010089A1 (en) | Modification of peptide and protein | |
| Xiong et al. | CAR-NK cell therapy for glioblastoma: what to do next? | |
| EP3720453B1 (en) | Modified lymphocytes | |
| AU2018277294A1 (en) | Oncolytic virus and method | |
| JP2024512608A5 (enExample) | ||
| Borgers et al. | Cellular therapy and cytokine treatments for melanoma | |
| KR20210065065A (ko) | 단백질 발현용 mRNA 구조체 및 이의 용도 | |
| JP2025519106A (ja) | 脂質ナノ粒子用のターゲティング体を有する修飾アポリポタンパク質 | |
| TW202300643A (zh) | 用於增強幹細胞樣記憶ｔ細胞工程改造之材料及方法 | |
| US20220195441A1 (en) | Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias |